WB, IP
H Mk
Endogenous
66
Rabbit IgG
#Q9UMX0
29979
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Immunoprecipitation | 1:50 |
Storage
Specificity / Sensitivity
Species Reactivity:
Human, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human UBQLN1 protein.
Background
Ubiquilin 1 (UBQLN1) is a ubiquitously expressed, type 2 ubiquitin like (UBL) protein that contains an amino-terminal UBL domain and a carboxy-terminal Ub-associated (UBA) domain (1). Research studies demonstrate that UBQLN1 associates with poly-Ub chains through its UBA domain, while the UBL domain participates in interactions with proteasome subunits. Evidence suggests that UBQLN1 acts as a shuttling factor during endoplasmic-reticulum-associated protein degradation (ERAD) as it transports misfolded, ubiquitinated proteins from the ER to the proteasome for subsequent degradation (2-5). Additional research studies demonstrate that the UBL domain of UBQLN1 binds UIM-containing endocytic proteins and participates in the sequestration of protein aggregates during aggresome formation (6,7). UBQLN1 regulates presenilin protein levels and is localized in neurofibrillary tangles of Alzheimer's disease-affected brains (8). Polymorphisms in the corresponding UBQLN1 gene may be associated with a risk of Alzheimer's disease (9-11).
- Hanaoka, E. et al. (2000) J Hum Genet 45, 188-91.
- Ko, H.S. et al. (2004) FEBS Lett 566, 110-4.
- Lim, P.J. et al. (2009) J Cell Biol 187, 201-17.
- Kleijnen, M.F. et al. (2000) Mol Cell 6, 409-19.
- Zhang, D. et al. (2008) J Mol Biol 377, 162-80.
- Heir, R. et al. (2006) EMBO Rep 7, 1252-8.
- Regan-Klapisz, E. et al. (2005) J Cell Sci 118, 4437-50.
- Mah, A.L. et al. (2000) J Cell Biol 151, 847-62.
- Yue, Z. et al. (2014) Int J Neurosci [Epub ahead of print ].
- Viswanathan, J. et al. (2011) Traffic 12, 330-48.
- Bertram, L. et al. (2005) N Engl J Med 352, 884-94.
Species Reactivity
Species reactivity is determined by testing in at least one approved application (e.g., western blot).
Western Blot Buffer
IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.
Applications Key
WB: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key
H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse GP: Guinea Pig Rab: rabbit All: all species expected
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.